Hiltzik: Are Dodos and Mammoths Coming Back From Extinction? Don't Count on It

Why It Matters

The announcement illustrates how de‑extinction hype can attract massive capital while potentially diverting attention and funds from protecting endangered species. It also underscores the risk of eroding public confidence in scientific claims when media coverage lacks critical scrutiny.

Key Takeaways

• Colossal hatched 26 chickens using an artificial eggshell incubator.
• Company raised $200 million, valuing it at $10.2 billion.
• Scientists warn de‑extinction may divert resources from living species.
• Media hype risks eroding public trust in biotech claims.

Pulse Analysis

The scientific community remains skeptical about de‑extinction, and for good reason. While Colossal’s artificial eggshell technology improves embryo oxygenation, bridging the gap from a chicken embryo to a viable moa or dodo requires reconstructing ancient genomes, mastering complex gestation in surrogate elephants, and addressing ecological mismatches that have evolved over centuries. Current progress—essentially a sophisticated incubator—does not constitute a meaningful stride toward resurrecting megafauna, and many biologists argue that the effort may be fundamentally infeasible without high‑quality DNA samples.

From a business perspective, Colossal’s ability to secure $200 million in funding and a $10.2 billion valuation demonstrates the allure of headline‑grabbing science for venture capital. Investors are drawn to the promise of CRISPR‑driven breakthroughs and the potential for lucrative patents in synthetic biology, even when the underlying science is still speculative. This funding influx, however, raises questions about opportunity cost: capital that could accelerate habitat restoration, anti‑poaching technologies, or gene‑editing for existing endangered species is being funneled into a narrative that may never materialize.

The media’s role amplifies the stakes. Sensational headlines—often lacking input from independent experts—fuel public excitement but also set unrealistic expectations. When hype outpaces reality, disappointment can damage credibility not only for the company but for the broader biotech sector, making future policy support for genuine conservation initiatives harder to secure. Balanced reporting that contextualizes technical milestones within the larger ecosystem of conservation science is essential to maintain trust and ensure that innovation serves tangible environmental outcomes.